Clinical trials in San Donato Milanese – page 100

2 835 clinical trials in San Donato Milanese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

San Donato Milanese at a glance

2 835

clinical trials

Research sites1

Quick filters

2 835 trials in San Donato Milanese

Open in trial search

Amyloidosis

Not yet recruiting

Evaluation of belantamab mafodotin plus drug combination in adult patients with newly diagnosed light chain amyloidosis

Registered drugNo placebo

Evaluation of belantamab mafodotin plus drug combination in adult patients with newly diagnosed light chain amyloidosis

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Bortezomib
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Focal segmental glomerulosclerosis

Not yet recruiting

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan
Sponsor:Apellis Pharmaceuticals Inc.

Contact Research Centre

Squamous cell carcinoma of skin

Not yet recruiting

Phase II Study of Cemiplimab to Spare Surgery in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo

Phase II Study of Cemiplimab to Spare Surgery in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Fondazione GONO Plus

Contact Research Centre

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Squamous cell carcinoma of lung

Not yet recruiting

Study of Cemiplimab, Platinum and Gemcitabine in Treatment‑Naïve Patients with Advanced Squamous Non‑Small Cell Lung Cancer

Registered drugNo placebo

Study of Cemiplimab, Platinum and Gemcitabine in Treatment‑Naïve Patients with Advanced Squamous Non‑Small Cell Lung Cancer

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Cemiplimab
Sponsor:G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Taletrectinib
Sponsor:Nuvation Bio Inc.

Contact Research Centre

Pulmonary hypertension

Not yet recruiting

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Treprostinil Palmitil
Sponsor:Insmed Inc.

Contact Research Centre

Thyroid cancer+1

Not yet recruiting

Study of levothyroxine sodium plus liothyronine sodium vs levothyroxine sodium to control TSH in advanced thyroid cancer patients on tyrosine kinase inhibitors

Registered drugNo placebo

Study of levothyroxine sodium plus liothyronine sodium vs levothyroxine sodium to control TSH in advanced thyroid cancer patients on tyrosine kinase inhibitors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Levothyroxine Sodium
Sponsor:Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.

Contact Research Centre

Benign prostatic hyperplasia

Not yet recruiting

Effect of serenoa repens on chronic prostate inflammation in men with benign prostatic hyperplasia: a phase III randomized study

Registered drug

Effect of serenoa repens on chronic prostate inflammation in men with benign prostatic hyperplasia: a phase III randomized study

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Serenoa repens
Sponsor:Azienda Ospedaliero Universitaria Careggi

Contact Research Centre

Metachromatic leukodystrophy

Not yet recruiting

Long‑Term Monitoring of Malignancy Risk in Early‑Onset Metachromatic Leukodystrophy Patients Treated with atidarsagene autotemcel

Registered drugNo placebo

Long‑Term Monitoring of Malignancy Risk in Early‑Onset Metachromatic Leukodystrophy Patients Treated with atidarsagene autotemcel

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years
Sponsor:Orchard Therapeutics (Europe) Limited

Contact Research Centre

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:CC-97540
Sponsor:Celgene Corp.

Contact Research Centre

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in San Donato Milanese

What the registry says about research in the country

01 Gastroenterology Research

Leading studies focusing on inflammatory bowel diseases, including investigations of novel treatments for Crohn's Disease and Ulcerative Colitis. Research encompasses both established and experimental therapies aimed at inducing clinical remission.

Crohn's Disease Management
Ulcerative Colitis Treatments
Fecal Incontinence Therapy

Multiple trials evaluating innovative therapeutic approaches for gastrointestinal conditions.

02 Cardiovascular Studies

Comprehensive research into heart conditions, with particular emphasis on hypertrophic cardiomyopathy and heart failure. Studies evaluate new medications and surgical interventions.

Heart Failure Management
Cardiac Surgery Outcomes
Myocardial Infarction Research

Innovative approaches in treating various cardiac conditions using precision medicine techniques.

03 Immunology Research

Groundbreaking studies in hereditary angioedema and chronic urticaria, investigating both preventive treatments and acute attack management strategies.

Hereditary Angioedema Treatments
Chronic Urticaria Management
Pediatric Immunology Studies

Advanced therapeutic options being developed for rare immunological disorders.

Back to Italy All countries